Table 5.

Associations of statin use with breast cancer mortality

Comparison	Model type	HR	95 % CI	p value
Baseline statin: yes versus no	Univariable	0.85	(0.56, 1.25)	0.435
	Multivariablea	0.91	(0.60, 1.37)	0.648
Baseline statin: by typeb	Univariable
Lipophilic versus none		0.72	(0.44, 1.17)	0.188
Hydrophilic versus none		1.31	(0.68, 2.54)	0.425
Lipophilic versus hydrophilic	Multivariablea	0.55	(0.25, 1.23)	0.147
Lipophilic versus none		0.75	(0.45, 1.25)	0.269
Hydrophilic versus none		1.49	(0.77, 2.90)	0.241
Lipophilic versus hydrophilic		0.50	(0.22, 1.14)	0.100
Statin use over time: yes versus no	Univariable	0.64	(0.38, 1.08)	0.095
	Multivariablea	0.59	(0.32, 1.06)	0.075

^aAdjusted for race (American Indian or Alaskan Native; Asian or Pacific Islander; Black or African–American; Hispanic/Latino; White), education (none to some HS; HS diploma/GED; vocational, training school, some college or associate degree; college degree or more), smoking (never smoked; past smoker; current smoker), BMI (<25; 25–29; ≥30), waist circumference (≤88 cm;>88 cm), mammogram in the past 2 years (no; yes), Gail 5-year risk (<1.67 %; ≥1.67 %), female relative with breast cancer(no; yes), age at menarche (≤11, 12–13; 14+), number of live births (never pregnant; none; 1–2; 3+, breast biopsy (no; yes), hysterectomy (no; yes), hormone use (never; past user; current user <5 years; current user 5 to <10 years; current user ≥10 years), oral contraceptive (no; yes), aspirin use (no; yes) and study component (observational study; estrogen alone clinical trial, estrogen + progesterone clinical trial; dietary modification clinical trial; estrogen/estrogen + progesterone and dietary modification clinical trial)

^bLipophilic (lovastatin, simvastatin, fluvastatin, atorvastatin), hydrophilic (pravastatin)